Sangeetha Sagar, PhD

Vice President / IAVI

International AIDS Vaccine Initiative 125 Broad Street, 9th Floor New York, NY 10004

Sangeetha Sagar leads IAVI’s efforts to rapidly advance the most promising vaccine and biologics candidates from the laboratory into clinical trials, accelerating the product development process.


Sangeetha Sagar has 29 years of experience in all aspects of CMC development and supply of vaccines, gene and cell therapy products, and mono and multispecific antibodies and conjugates.  She previously worked for various large biopharma companies, leading end-to-end development of vaccines and biotherapeutics for Ebola, Covid, HPV and more. Her goal is to play a pivotal role in developing vaccines and medicine that prevent and treat global infectious diseases and reach those in greatest need.

Training and Education

  • 1993
    Post-Doctoral Fellowship, Biochemistry: Structure-Function Relationships of Biomolecules, C.N.R.S-N.I.H., Marseille, France
  • 1992
    PhD, Chemical Engineering and Biomedical Engineering Science, Carnegie Mellon University
  • 1988
    BS, Chemical Engineering, Biomedical Engineering Minor with Pre-Med, University of Colorado at Boulder